App aims to ease menopause symptoms without medication
NCT ID NCT07663305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a mobile app can help women cope with menopause symptoms like hot flashes and sleep problems. About 426 women with medically confirmed menopause symptoms are randomly assigned to use the app alongside their usual care or to continue with usual care alone. The app provides tools like a symptom diary and guided exercises. Researchers measure changes in quality of life and symptom severity over 12 to 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Menopause App (digital self-management tool)
- What this could lead to
- If effective, this app could offer women a convenient, non-drug way to ease menopause symptoms and improve daily life.
- What could go wrong
- The app is a digital tool, not a medical treatment. Its benefits may be modest, and results depend on regular use and individual motivation.
Why investors are watching
Endo, Inc. is a micro-cap company, and its subsidiary Endo Health GmbH is running a 24-week trial of a mobile app for menopause symptoms in 426 women. The readout matters because a positive result could give the company a marketable digital health product, while a negative result would leave it with little to show for the effort.
If it works: If the app improves menopause-specific quality of life at 12 weeks, Endo, Inc. could have evidence to support commercializing the app or partnering with larger health companies. That could create a new revenue stream for a company of this size.
If it fails: The trial could fail to show a benefit over usual care, which happens often in digital health studies. A failure or delay would likely set back Endo, Inc.'s plans and could reduce investor confidence in its pipeline.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 426 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Legal capacity * Ability to provide informed consent * Residency in Germany * Female gender * Age ≥18 years * Medically confirmed menopausal or other perimenopausal disorder (N95.1) * Ownership of a smartphone and ability to use it * Internet access for app usage and questionnaire completion * Email address for registration * Willingness to complete questionnaires online * Motivation for regular app usage * Sufficient proficiency in the German language * MRS II ≥ 9 * Absence of exclusion criteria Exclusion Criteria: * Pregnancy or breastfeeding during the study period * Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period * Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period * Start of psychotherapy within eight weeks prior to study start and/or planned during the study period * Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period * Surgery performed within eight weeks prior to study start and/or planned during the study period * Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription * Current participation in other clinical studies * Failure to meet the inclusion criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for N95.1 menopausal and female climacteric states are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medicoles
Hanover, Germany